| Population 2012
|
<1 million
|
| |
| | |
| Estimates of TB burden * 2012
|
Number (thousands)
|
Rate
(per 100 000 population)
|
| Mortality (excludes HIV+TB)
|
<0.01
|
(<0.01–<0.01)
|
0.19
|
(0.13–0.25)
|
| Mortality (HIV+TB only)
|
<0.01
|
(0–<0.01)
|
0.02
|
(0–0.17)
|
| Prevalence (includes HIV+TB)
|
0.15
|
(0.065–0.28)
|
25
|
(10–45)
|
| Incidence (includes HIV+TB)
|
0.11
|
(0.1–0.13)
|
18
|
(16–20)
|
| Incidence (HIV+TB only)
|
<0.01
|
(0–<0.01)
|
0.05
|
(0–0.54)
|
| Case detection, all forms (%)
|
87
|
(78–97)
|
|
|
| |
| | |
| TB case notifications 2012
|
|
|
|
|
| New cases
|
|
(%)
|
Retreatment cases
|
(%)
|
| Smear-positive
|
45
|
(48)
|
Relapse
|
4
|
(31)
|
| Smear-negative
|
33
|
(35)
|
Treatment after failure
|
0
|
(0)
|
| Smear-unknown / not done
|
3
|
(3)
|
Treatment after default
|
0
|
(0)
|
| Extrapulmonary
|
13
|
(14)
|
Other
|
9
|
(69)
|
| Other
|
0
|
(0)
|
|
|
|
| Total new
|
94
|
|
Total retreatment
|
13
|
|
|
|
|
|
|
|
|
| Other (history unknown)
|
0
|
|
|
|
|
| Total new and relapse
|
98
|
|
Total cases notified
|
107
|
|
| |
| | |
| New cases
|
Smear-positive
|
Smear-negative/ unknown/
not done
|
Extrapulmonary
|
| M:F ratio
|
1.8
|
1.8
|
0.6
|
| Age < 15
|
0
|
0
|
0
|
| | |
| | |
| Laboratories
|
2012
|
| Smear (per 100 000 population)
|
0.2
|
| Culture (per 5 million population)
|
8.1
|
| Drug susceptibility testing (per 5 million population)
|
8.1
|
| Is second-line drug susceptibility testing available?
|
Yes, outside
country
|
| |
| | |
| Treatment success rate 2011 (%)
|
|
|
|
|
| New smear-positive and/or culture-positive
|
86
|
|
Is rifampicin used
throughout treatment for
new patients?
|
Yes
|
| New smear-negative/extrapulmonary
|
86
|
|
| Retreatment
|
83
|
|
| |
| | |
| TB/HIV 2012
|
Number
|
(%)
|
| TB patients with known HIV status
|
82
|
(77)
|
| HIV-positive TB patients
|
0
|
(0)
|
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)
|
0
|
|
| HIV-positive TB patients on antiretroviral therapy (ART)
|
0
|
|
| HIV-positive people screened for TB
|
|
|
| HIV-positive people provided with IPT
|
|
|
| | |
| | |
| Estimates of MDR-TB burden 2012*
|
|
New
|
|
Retreatment
|
| % of TB cases with MDR-TB
|
0
|
(0–6.2)
|
0
|
(0–52)
|
MDR-TB cases among notified pulmonary
TB cases
|
0
|
(0–5)
|
0
|
(0–7)
|
| |
| | |
| Reported cases of MDR-TB 2012
|
New
|
Retreatment
|
Total
|
| Cases tested for MDR-TB
|
58 (98%)
|
5 (38%)
|
63
|
| Laboratory-confirmed MDR-TB cases
|
0
|
0
|
0
|
| Patients started on MDR-TB treatment
|
|
|
0
|
| |
| | |
| Financing TB control
|
2013
|
| National TB programme budget (US$ millions)
|
<1
|
| % Funded domestically
|
73%
|
| % Funded internationally
|
|
| % Unfunded
|
27%
|
| |
| | |